Esperion Therapeutis.Inc. buy Bankster
Summary
This prediction ended on 29.03.24 with a price of €2.78. With a performance of 3.27%, the BUY prediction by Bankster for Esperion Therapeutis.Inc. closed with a slight gain. Bankster has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Esperion Therapeutis.Inc. | -9.871% | -9.871% |
iShares Core DAX® | -0.612% | 0.567% |
iShares Nasdaq 100 | -3.018% | -3.205% |
iShares Nikkei 225® | -2.647% | 0.330% |
iShares S&P 500 | -1.932% | -1.126% |
Comments by Bankster for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren
In the thread Trading Esperion Therapeutis.Inc.
Stopped prediction by Bankster for Esperion Therapeutis.Inc.
Esperion Therapeutis.Inc.
13.03.23
13.03.24
03.04.23